GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » Change In Prepaid Assets

Dermata Therapeutics (Dermata Therapeutics) Change In Prepaid Assets : $0.08 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Change In Prepaid Assets?

Dermata Therapeutics's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was $0.09 Mil. It means Dermata Therapeutics's Prepaid Assets increased by $0.09 Mil from Dec. 2023 to Mar. 2024 .

Dermata Therapeutics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $0.16 Mil. It means Dermata Therapeutics's Prepaid Assets increased by $0.16 Mil from Dec. 2022 to Dec. 2023 .

Dermata Therapeutics Change In Prepaid Assets Historical Data

The historical data trend for Dermata Therapeutics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics Change In Prepaid Assets Chart

Dermata Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Prepaid Assets
0.05 - -0.75 0.12 0.16

Dermata Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.25 -0.42 0.15 0.09

Dermata Therapeutics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermata Therapeutics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermata Therapeutics (Dermata Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » Change In Prepaid Assets
Comparable Companies
SCPS AMPE RVLPQ PKBO ATXI NBRVF BXRX ADTX SONN GSTC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130
Website
https://www.dermatarx.com
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Executives
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl 10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K. officer: Chief Financial Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga director C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott director C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley officer: Chief Financial Officer SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E officer: Senior VP 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler director 1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo officer: Senior VP, Development C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc 10 percent owner C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130